Literature DB >> 28041316

CyberKnife stereotactic radiosurgery for the treatment of symptomatic vertebral hemangiomas: a single-institution experience.

Michael Zhang1, Yi-Ren Chen1, Steven D Chang1, Anand Veeravagu1.   

Abstract

OBJECTIVE Symptomatic vertebral hemangiomas (SVHs) are a very rare pathology that can present with persistent pain or neurological deficits that warrant surgical intervention. Given the relative rarity and difficulty in assessment, the authors sought to present a dedicated series of SVHs treated using stereotactic radiosurgery (SRS) to provide insight into clinical decision making. METHODS A retrospective review of a single institution's experience with hypofractionated radiosurgery for SVH from 2004 to 2011 was conducted to determine the clinical and radiographic outcomes following SRS treatment. The authors report and analyze the treatment course of 5 patients with 7 lesions, 2 of which were treated primarily by SRS. RESULTS Of the 5 patients studied, 4 presented with a chief complaint of pain refractory to conservative measures. Three patients reported dysesthesias, and 2 reported upper-extremity weakness. Following radiosurgery, 4 of 5 patients exhibited improvement in their primary symptoms (3 for pain and 1 for weakness), achieving a clinical response after a mean period of 1 year. In 2 cases there was 20%-40% reduction in lesion size in the most responsive dimension as noted on images. All treatments were well tolerated. CONCLUSIONS SRS for SVH is a safe and feasible treatment strategy, comparable to prior radiotherapy studies, and in select cases may successfully confer delayed decompressive effects. Additional investigation will determine future patient selection and how conformal SRS treatment can best be administered.

Entities:  

Keywords:  BED = biologically effective dose; CyberKnife; SRS = stereotactic radiosurgery; SVH = symptomatic vertebral hemangioma; hypofractionation; nBED = normalized BED; spine; stereotactic radiosurgery; symptomatic vertebral hemangioma

Mesh:

Year:  2017        PMID: 28041316     DOI: 10.3171/2016.9.FOCUS16372

Source DB:  PubMed          Journal:  Neurosurg Focus        ISSN: 1092-0684            Impact factor:   4.047


  7 in total

1.  Early response assessment after CyberKnife stereotactic radiosurgery for symptomatic vertebral hemangioma by quantitative parameters from dynamic contrast-enhanced MRI.

Authors:  Hongqing Zhuang; Ning Lang; Yongye Chen; Enlong Zhang; Qizheng Wang; Huishu Yuan
Journal:  Eur Spine J       Date:  2021-03-01       Impact factor: 3.134

2.  Case report: Cyberknife radiosurgery for the treatment of disabling pain caused by vertebral body hemangioma.

Authors:  Eduardo Gaviolli; John Sinclair; Shawn Malone
Journal:  J Radiosurg SBRT       Date:  2020

3.  Symptomatic Vertebral Hemangioma of the Posterior Elements Sharing Blood Supply with a Radiculomedullary Artery.

Authors:  Amit R Persad; Richard J Fox; Jeremy L Rempel
Journal:  Int J Spine Surg       Date:  2018-08-31

4.  Radiotherapy for vertebral hemangioma: the single-center experience of 80 patients.

Authors:  Rahmi Atil Aksoy; Melek Gamze Aksu; Aylin Fidan Korcum; Mine Genc
Journal:  Strahlenther Onkol       Date:  2022-03-12       Impact factor: 4.033

Review 5.  Progression of aggressive vertebral hemangiomas during pregnancy: Three case reports and literature review.

Authors:  Ben Wang; Liang Jiang; Feng Wei; Xiao Guang Liu; Zhong Jun Liu
Journal:  Medicine (Baltimore)       Date:  2018-10       Impact factor: 1.817

6.  The Role of Radiotherapy and Surgery in the Management of Aggressive Vertebral Hemangioma: A Retrospective Study of 20 Patients.

Authors:  Ben Wang; Na Meng; Hongqing Zhuang; Songbo Han; Shaomin Yang; Liang Jiang; Feng Wei; Xiaoguang Liu; Zhongjun Liu
Journal:  Med Sci Monit       Date:  2018-09-27

7.  Prevalence of benign osseous lesions of the spine and association with spinal pain in the general population in whole body MRI.

Authors:  Richard Kasch; Josephin Scheele; Mark Hancock; André Hofer; Christopher Maher; Robin Bülow; Jörn Lange; Andreas Lahm; Matthias Napp; Georgi Wassilew; Carsten Oliver Schmidt
Journal:  PLoS One       Date:  2019-09-09       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.